Anxiety Rating Scales in Parkinson's Disease: A Validation Study of the Hamilton Anxiety Rating Scale, the Beck Anxiety Inventory, and the Hospital Anxiety and Depression Scale
Identifieur interne : 001D44 ( PascalFrancis/Checkpoint ); précédent : 001D43; suivant : 001D45Anxiety Rating Scales in Parkinson's Disease: A Validation Study of the Hamilton Anxiety Rating Scale, the Beck Anxiety Inventory, and the Hospital Anxiety and Depression Scale
Auteurs : Albert F. G. Leentjens [Pays-Bas] ; Kathy Dujardin [France] ; Laura Marsh [États-Unis] ; Irene H. Richard [États-Unis] ; Sergio E. Starkstein [Australie] ; Pablo Martinez-Martin [Espagne]Source :
- Movement disorders [ 0885-3185 ] ; 2011.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Background: Anxiety is a prevalent and disabling condition in Parkinson's disease (PD). The lack of anxiety rating scales validated for this population hampers research into anxiety in PD. The aim of this study is to assess the clinimetric properties of the Hamilton anxiety rating scale (HARS), the Beck anxiety inventory (BAI), and the hospital anxiety and depression scale (HADS) in PD patients. Design: Three hundred forty-two PD patients underwent a standardized assessment including a structured interview for diagnostic and statistical manual diagnoses of anxiety disorders and completion of the HARS, BAI, and HADS. Inter-rater reliability of the HARS was assessed in 60 patients; test-retest reliability of the BAI and HADS in 213 and 217 patients, respectively. Results: Thirty-four percent of patients suffered from an anxiety disorder, whereas an additional 11.4% had clinically significant anxiety symptoms in the absence of a diagnosis of anxiety disorder. Acceptability, score distribution, and known groups validity over different levels of anxiety were adequate. Inter-rater reliability for the HARS and test-retest reliability for the BAI and HADS were good. The HARS, but not the BAI and HADS, had a satisfactory inter-item correlation, convergent validity and factorial structure. For all scales, the positive predictive value was poor, and the negative predictive value was moderate. Conclusions: Given the adequate known groups validity of all three rating scales, each of these scales is likely to be useful in clinical practice or research for evaluation of symptom severity. Limitations in the construct validity of the anxiety scales in this study raise questions regarding suitability for their use in PD.
Affiliations:
- Australie, Espagne, France, Pays-Bas, États-Unis
- Communauté de Madrid, Hauts-de-France, Maryland, Nord-Pas-de-Calais, État de New York
- Lille, Madrid
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:11-0211270Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Anxiety Rating Scales in Parkinson's Disease: A Validation Study of the Hamilton Anxiety Rating Scale, the Beck Anxiety Inventory, and the Hospital Anxiety and Depression Scale</title><author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Medical Center</s1><s2>Maastricht</s2><s3>NLD</s3><sZ>1 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>Maastricht</wicri:noRegion></affiliation></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Psychiatry, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name><affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Department of Psychiatry, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>School of Psychiatry, University of Western Australia and Fremantle Hospital</s1><s2>Fremantle, Western Australia</s2><s3>AUS</s3><sZ>5 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Fremantle, Western Australia</wicri:noRegion></affiliation></author><author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health</s1><s2>Madrid</s2><s3>ESP</s3><sZ>6 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0211270</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0211270 INIST</idno><idno type="RBID">Pascal:11-0211270</idno><idno type="wicri:Area/PascalFrancis/Corpus">001E15</idno><idno type="wicri:Area/PascalFrancis/Curation">004125</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001D44</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001D44</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Anxiety Rating Scales in Parkinson's Disease: A Validation Study of the Hamilton Anxiety Rating Scale, the Beck Anxiety Inventory, and the Hospital Anxiety and Depression Scale</title><author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Medical Center</s1><s2>Maastricht</s2><s3>NLD</s3><sZ>1 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>Maastricht</wicri:noRegion></affiliation></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Psychiatry, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name><affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Department of Psychiatry, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>School of Psychiatry, University of Western Australia and Fremantle Hospital</s1><s2>Fremantle, Western Australia</s2><s3>AUS</s3><sZ>5 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Fremantle, Western Australia</wicri:noRegion></affiliation></author><author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health</s1><s2>Madrid</s2><s3>ESP</s3><sZ>6 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anxiety</term><term>Depression</term><term>Evaluation scale</term><term>Hospital</term><term>Inventory</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Psychometrics</term><term>Reliability</term><term>Validation</term><term>Validity</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Angoisse anxiété</term><term>Maladie de Parkinson</term><term>Etat dépressif</term><term>Pathologie du système nerveux</term><term>Validation</term><term>Echelle d'évaluation</term><term>Inventaire</term><term>Hôpital</term><term>Psychométrie</term><term>Validité</term><term>Fiabilité</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Anxiety is a prevalent and disabling condition in Parkinson's disease (PD). The lack of anxiety rating scales validated for this population hampers research into anxiety in PD. The aim of this study is to assess the clinimetric properties of the Hamilton anxiety rating scale (HARS), the Beck anxiety inventory (BAI), and the hospital anxiety and depression scale (HADS) in PD patients. Design: Three hundred forty-two PD patients underwent a standardized assessment including a structured interview for diagnostic and statistical manual diagnoses of anxiety disorders and completion of the HARS, BAI, and HADS. Inter-rater reliability of the HARS was assessed in 60 patients; test-retest reliability of the BAI and HADS in 213 and 217 patients, respectively. Results: Thirty-four percent of patients suffered from an anxiety disorder, whereas an additional 11.4% had clinically significant anxiety symptoms in the absence of a diagnosis of anxiety disorder. Acceptability, score distribution, and known groups validity over different levels of anxiety were adequate. Inter-rater reliability for the HARS and test-retest reliability for the BAI and HADS were good. The HARS, but not the BAI and HADS, had a satisfactory inter-item correlation, convergent validity and factorial structure. For all scales, the positive predictive value was poor, and the negative predictive value was moderate. Conclusions: Given the adequate known groups validity of all three rating scales, each of these scales is likely to be useful in clinical practice or research for evaluation of symptom severity. Limitations in the construct validity of the anxiety scales in this study raise questions regarding suitability for their use in PD.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>26</s2></fA05><fA06><s2>3</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Anxiety Rating Scales in Parkinson's Disease: A Validation Study of the Hamilton Anxiety Rating Scale, the Beck Anxiety Inventory, and the Hospital Anxiety and Depression Scale</s1></fA08><fA11 i1="01" i2="1"><s1>LEENTJENS (Albert F. G.)</s1></fA11><fA11 i1="02" i2="1"><s1>DUJARDIN (Kathy)</s1></fA11><fA11 i1="03" i2="1"><s1>MARSH (Laura)</s1></fA11><fA11 i1="04" i2="1"><s1>RICHARD (Irene H.)</s1></fA11><fA11 i1="05" i2="1"><s1>STARKSTEIN (Sergio E.)</s1></fA11><fA11 i1="06" i2="1"><s1>MARTINEZ-MARTIN (Pablo)</s1></fA11><fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Medical Center</s1><s2>Maastricht</s2><s3>NLD</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Psychiatry, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="05"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Psychiatry, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="07"><s1>School of Psychiatry, University of Western Australia and Fremantle Hospital</s1><s2>Fremantle, Western Australia</s2><s3>AUS</s3><sZ>5 aut.</sZ></fA14><fA14 i1="08"><s1>Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health</s1><s2>Madrid</s2><s3>ESP</s3><sZ>6 aut.</sZ></fA14><fA20><s1>407-415</s1></fA20><fA21><s1>2011</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000190875360060</s5></fA43><fA44><s0>0000</s0><s1>© 2011 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>42 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>11-0211270</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Background: Anxiety is a prevalent and disabling condition in Parkinson's disease (PD). The lack of anxiety rating scales validated for this population hampers research into anxiety in PD. The aim of this study is to assess the clinimetric properties of the Hamilton anxiety rating scale (HARS), the Beck anxiety inventory (BAI), and the hospital anxiety and depression scale (HADS) in PD patients. Design: Three hundred forty-two PD patients underwent a standardized assessment including a structured interview for diagnostic and statistical manual diagnoses of anxiety disorders and completion of the HARS, BAI, and HADS. Inter-rater reliability of the HARS was assessed in 60 patients; test-retest reliability of the BAI and HADS in 213 and 217 patients, respectively. Results: Thirty-four percent of patients suffered from an anxiety disorder, whereas an additional 11.4% had clinically significant anxiety symptoms in the absence of a diagnosis of anxiety disorder. Acceptability, score distribution, and known groups validity over different levels of anxiety were adequate. Inter-rater reliability for the HARS and test-retest reliability for the BAI and HADS were good. The HARS, but not the BAI and HADS, had a satisfactory inter-item correlation, convergent validity and factorial structure. For all scales, the positive predictive value was poor, and the negative predictive value was moderate. Conclusions: Given the adequate known groups validity of all three rating scales, each of these scales is likely to be useful in clinical practice or research for evaluation of symptom severity. Limitations in the construct validity of the anxiety scales in this study raise questions regarding suitability for their use in PD.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Angoisse anxiété</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Anxiety</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Angustia ansiedad</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Etat dépressif</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Depression</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Estado depresivo</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Validation</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Validation</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Validación</s0><s5>09</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Echelle d'évaluation</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Evaluation scale</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Escala evaluación</s0><s5>10</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Inventaire</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Inventory</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Inventario</s0><s5>11</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Hôpital</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Hospital</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Hospital</s0><s5>12</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Psychométrie</s0><s5>13</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Psychometrics</s0><s5>13</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Psicometría</s0><s5>13</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Validité</s0><s5>14</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Validity</s0><s5>14</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Validez</s0><s5>14</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Fiabilité</s0><s5>15</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Reliability</s0><s5>15</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Fiabilidad</s0><s5>15</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Affect affectivité</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Affect affectivity</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Afecto afectividad</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>41</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Trouble de l'humeur</s0><s5>43</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Mood disorder</s0><s5>43</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Trastorno humor</s0><s5>43</s5></fC07><fN21><s1>143</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Australie</li><li>Espagne</li><li>France</li><li>Pays-Bas</li><li>États-Unis</li></country><region><li>Communauté de Madrid</li><li>Hauts-de-France</li><li>Maryland</li><li>Nord-Pas-de-Calais</li><li>État de New York</li></region><settlement><li>Lille</li><li>Madrid</li></settlement></list><tree><country name="Pays-Bas"><noRegion><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name></noRegion></country><country name="France"><region name="Hauts-de-France"><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name></region></country><country name="États-Unis"><region name="Maryland"><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name></region><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name></country><country name="Australie"><noRegion><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name></noRegion></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D44 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 001D44 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:11-0211270
|texte= Anxiety Rating Scales in Parkinson's Disease: A Validation Study of the Hamilton Anxiety Rating Scale, the Beck Anxiety Inventory, and the Hospital Anxiety and Depression Scale
}}
| This area was generated with Dilib version V0.6.33. |  |